Merck (NYSE:MRK) KGaA MKGAF is a science and technology company in healthcare, life science and performance materials. Founded in 1668, it is the world's oldest pharmaceutical and chemical company.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
The company lead candidate, avelumab, is being evaluated in phase III studies for several cancer indications, in collaboration with Pfizer (NYSE:PFE).
The recent the acquisition of Sigma-Aldrich (NASDAQ:SIAL) led the company to gain access to an attractive set of established brands along with an efficient supply chain to support the delivery of over 300,000 products, thereby enabling it to customers all over the world.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5, compared to the year-ago figure of 70 cents.
Revenue: The company posted revenues of $4 billion in the reported quarter.
Key Stats: All three business units continued to perform well in the first quarter. The acquisition of Sigma-Aldrich boosted sales in the reported quarter. For 2016, the company expects net sales in the range of €14.8–€15 billion. Backed by the Sigma-Aldrich acquisition, the company expects a positive portfolio effect on sales in the low double-digit percentage range.
Check back later for our full write up on earnings report later!
Original post
Zacks Investment Research